Molbio Diagnostics IPO

Molbio Diagnostics Limited was incorporated in 2000 and is a point-of-care (POC) diagnostics company dedicated to the development of affordable, rapid, and accurate healthcare solutions for infectious and non-communicable diseases.

Molbio Diagnostics has introduced the ‘Truenat’ system, which is a portable PCR system capable of delivering decentralized diagnosis in less than one hour. By March 31, 2025, this system has been patented in more than 100 countries and offers molecular testing of 30 diseases including TB, COVID, Hepatitis B and C, HIV, and HPV using 42 assays. The ‘Truenat’ TB test is one of only two WHO-recommended rapid molecular tests for initial diagnosis of TB and detecting rifampicin resistance.

The company also provides services relating to radiology, digital pathology, and breast health screening through its subsidiary Prognosys, its associate OptraScan, and collaboration partner UE Lifesciences.

Molbio Diagnostics maintains five manufacturing facilities in India: two in Goa, one in Visakhapatnam, Andhra Pradesh, and two in Bengaluru, Karnataka. These facilities manufacture diagnostic devices, test kits, and radiology devices including ultra-portable and mobile X-ray systems.

The company is an international company operating in more than 80 nations across the world with 33 international distributors and having sold more than 10,000 instruments up to March 31, 2025. Instruments are provided by the company both directly and through distributors to public health care programs, laboratories, and hospitals.

The company earns money from the sale of instruments along with recurring income from proprietary test kits.As on March 31, 2025, the company had 1,000 full-time employees and 1,511 contractual laborers.